Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Untreated Transplant-eligible Patients with Symptomatic MM to Evaluate the Benefit of Upfront ASCT (Cardamon)

NCT02315716 Phase 2 ACTIVE_NOT_RECRUITING

The Cardamon trial is a phase 2 trial using the standard chemotherapy drugs cyclophosphamide and dexamethasone in combination with a new drug called Carfilzomib in patients with multiple myeloma.

Details

Lead sponsor	University College, London
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	281
Start date	2015-06-16
Completion	2029-11

Conditions

• Multiple Myeloma

Interventions

• Autologous Stem Cell Transplant (ASCT)
• Consolidation with 4 cycles of CarCyDex

Primary outcomes

• Response rate — Within 4 weeks of the end of induction treatment
  Major response rate (sCR, CR \& VGPR) to 4 cycles of CarCyDex
• PFS — 2 years after randomisation
  Progression free survival at 2 years for both ASCT and non-ASCT (consolidation) arms

Countries

United Kingdom